To go beyond scientific theory and laboratory discoveries, FDA approved clinical trials are essential to finding a cure.
Crizanlizumab for Treatment of Retinal Vasculopathy with Cerebral Leukoencephalopathy (RVCL)
STUDY IDENTIFIER: 844604
Retinal vasculopathy with cerebral leukoencephalopathy (RVCL) is a very rare and fatal genetic condition that affects the smallest blood vessels, especially of the brain and eye. It causes damage in the brain and eye, and there is currently no treatment to reduce these areas of damage. Crizanlizumab has been shown to treat similar symptoms in other diseases, and it’s hypothesized that treating RVCL patients with crizanlizumab will slow the progression of this damage.
Patients diagnosed with retinal vasculopathy with cerebral leukoencephalopathy (RVCL) by Dr. Jonathan Miner at the University of Pennsylvania.